Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,612.40
(
0.11%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
95.14
(
-5.97%
)
Bitcoin
76,595.28
(
-0.87%
)
News Focus
News Focus
Post# of 257628
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 169158

Saturday, 11/02/2013 1:32:30 PM

Saturday, November 02, 2013 1:32:30 PM

Post# of 257628

ARIA—If they were going for true 3rd-line (T315I or failed both 2nd line drugs) then I am pretty sure the FDA would approve.

For non-T315I patients, we’re really talking about a fourth-line treatment. ARIA longs dismiss Bosulif as irrelevant, but that’s no longer a tenable viewpoint, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today